Skip to main content
SpringerLink
Log in

Eltrombopag may be cost effective for thrombocytopenia and PGF post transplantation

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Nampoothiri RV, et al. Efficacy and cost analysis of eltrombopag in thrombocytopenia and poor graft function post allogeneic hematopoietic cell transplantation. . Bone Marrow Transplantation : 9 Jun 2021. Available from: URL: http://doi.org/10.1038/s41409-021-01362-2

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eltrombopag may be cost effective for thrombocytopenia and PGF post transplantation. PharmacoEcon Outcomes News 881, 13 (2021). https://doi.org/10.1007/s40274-021-7809-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7809-6

Search

Navigation